Skip to main content
SpringerLink
Log in

Cancer of the Bladder

  • Chapter
Surgical Oncology

  • 263 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Pycha A, Mian C, Hofbauer J, et al. Multifocality of transitional cell carcinoma results from genetic instability of entire transitional epithelium. Urology 1999;53:92–97.

    Article  CAS  PubMed  Google Scholar 

  2. Sidransky D, Frost P, Von Eschenbach A, Oyasu R, Preisinger AC, Vogelstein V. Clonal origin of bladder cancer. N Engl J Med 1992;326:759–761.

    Article  Google Scholar 

  3. Chern H-D, Becich MJ, Persad RA, et al. Clonal analysis of human recurrent superficial bladder cancer by immunohistochemistry of P53 and retinoblastoma proteins. J Urol 1996;156:1846–1849.

    Article  CAS  PubMed  Google Scholar 

  4. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. Cancer 1999;49:8–31.

    CAS  Google Scholar 

  5. Vineis P. Epidemiological models of carcinogenesis: the example of bladder cancer. Cancer Epidemiol Biomarkers Prev 1992;1:149–153.

    CAS  PubMed  Google Scholar 

  6. Navon JD, Soliman H, Khonsari F, Ahlering T. Screening cystoscopy and survival of spinal cord injured patients with squamous cell cancer of the bladder. J Urol 1997;157:2109–2111.

    Article  CAS  PubMed  Google Scholar 

  7. Fernandes ET, Manivel JC, Reddy PK, Ercole CJ. Cyclophosphamide associated bladder cancer: a highly aggressive disease: Analysis of 12 cases. J Urol 1996;156:1931–1933.

    Article  CAS  PubMed  Google Scholar 

  8. Sijmons RH, Kiemeney LA, Witjes JA, Vasen HF. Urinary tract cancer and hereditary nonpolyposis colorectal cancer: Risks and screening options. J Urol 1998;160:466–470.

    Article  CAS  PubMed  Google Scholar 

  9. Grossman HB, Tex WA, Moncrief D. Superficial bladder cancer: Decreasing the risk of recurrence. Oncology 1996;10:1617.

    CAS  PubMed  Google Scholar 

  10. O’Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL. Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res 1995;55:510–513.

    CAS  PubMed  Google Scholar 

  11. Smits G, Schaafsma E, Kiemeney L, Caris C, Debruyne F, Witjes JA. Microstaging of pT1 transitional cell carcinoma of the bladder: Identification of subgroups with distinct risks of progression. Urol 1998;52:1009–1013.

    Article  CAS  PubMed  Google Scholar 

  12. Kroft SH, Oyasu R. Urinary bladder cancer: Mechanisms of development and progression. Laboratory Invest 1994;71:158–174.

    CAS  Google Scholar 

  13. Smith K, Fennelly JA, Neal DE, Hall RR, Harris AL. Characterization and quantitation of the epidermal growth factor receptor in invasive and superficial bladder tumors. Cancer Res 1989;49:5810–5815.

    CAS  PubMed  Google Scholar 

  14. Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331:1259–1264.

    Article  CAS  PubMed  Google Scholar 

  15. Lamm DL. Bladder cancer: twenty years of progress and the challenges that remain. Cancer 1998;48:263–284.

    CAS  Google Scholar 

  16. Scher H, Bahnson R, Cohen S, et al. NCCN urothelial cancer practice guidelines. Oncology 1998;12:225–271.

    CAS  PubMed  Google Scholar 

  17. Konety BR, Getzengerg RH. Urine based markers of urological malignancy. J Urol 2001;165:600–611.

    Article  CAS  PubMed  Google Scholar 

  18. Sharody MF, DeVere White RW, Soloway MS, et al. Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol 1995;154:379–384.

    Article  Google Scholar 

  19. Soloway MS, Briggman JV, Carpinito GA, et al. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 1996;156:363–367.

    Article  CAS  PubMed  Google Scholar 

  20. Lin Y, Miyamoto H, Fujinami K, et al. Telomerase activity in human bladder cancer. Clin Cancer Res 1996;2:929–932.

    CAS  PubMed  Google Scholar 

  21. Johnston B, Morales A, Emerson L, Lundie M. Rapid detection of bladder cancer: a comparative study of point of care tests. J Urol 1997;158:2098–2101.

    Article  CAS  PubMed  Google Scholar 

  22. Lokeshwar VB, Obek C, Soloway MS, Block NL. Tumor-associated hyaluronic acid: A new sensitive and specific urine marker for bladder cancer. J Urol 1997;57:773–777.

    CAS  Google Scholar 

  23. Ramakumar S, Bhuiyan J, Besse JA, et al. Comparison of screening methods in the detection of bladder cancer. J Urol 1999;161:388–384.

    Article  CAS  PubMed  Google Scholar 

  24. Hudson MA, Herr HW. Carcinoma in situ of the bladder. J Urol 1995;153:564–572.

    Article  CAS  PubMed  Google Scholar 

  25. Coplen DE, Marcus MD, Myers JA, Ratliff TL, Catalona WJ. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guéin: analysis of possible predictors of response free of tumor. J Urol 1990;144:652–665.

    CAS  PubMed  Google Scholar 

  26. Nadler RB, Catalona WJ, Hudson MA, et al. Durability of the tumor-free response for intravesical bacillus Calmette-Guéin therapy. J Urol 1994;152:367–373.

    CAS  PubMed  Google Scholar 

  27. Lamm DL, Riggs DR, Shriver JS, van Gilder PF, Rach JF, DeHaven JI. Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol 1994;151:21–26.

    CAS  PubMed  Google Scholar 

  28. Lamm DL. BCG immunotherapy for transitional-cell carcinoma in situ of the bladder. Oncology 1995;9:947–965.

    CAS  PubMed  Google Scholar 

  29. Lacombe L, Dalbagni G, Zhang Z-E, et al. Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guéin therapy: correlation to clinical outcome. Clin Onc 1997;14:2646–2642.

    Google Scholar 

  30. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol 1994;152:388–382.

    CAS  PubMed  Google Scholar 

  31. Lundholm C, Norlen BJ, Ekman P, et al. A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guéin in patients with superficial bladder carcinoma. J Urol 1996;156:372–376.

    Article  CAS  PubMed  Google Scholar 

  32. Greenberg RE, Bahnson RR, Wood D, et al. Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder. Urology 1997;49:471–475.

    Article  CAS  PubMed  Google Scholar 

  33. Belldegrun AS, Franklin JF, O’Donnell MA, et al. Superficial bladder cancer: the role of interferon-alpha. J Urol 1998;159:1793–1801.

    Article  CAS  PubMed  Google Scholar 

  34. Nseyo UO, Shumaker B, Klein EA, et al. Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. J Urol 1998;160:39–44.

    Article  CAS  PubMed  Google Scholar 

  35. Hillyard RW Jr, Ladaga L, Schellhammer PF. Superficial transitional cell carcinoma of the bladder associated with mucosal involvement of the prostatic urethra: results of treatment with intravesical bacillus Calmette-Guéin. J Urol 1988;139:290–293.

    PubMed  Google Scholar 

  36. Hermann GG, Horn T, Steven K. The influence of the level of lamina propria invasion and the prevalence of p53 nuclear accumulation on survival in stage T1 transitional cell bladder cancer. J Urol 1998;159:91–94.

    Article  CAS  PubMed  Google Scholar 

  37. Holmang S, Hedelin H, Anderstrom C, Holmberg E, Johansson SL. The importance of the depth of invasion of stage T1 bladder carcinoma: a prospective cohort study. J Urol 1997;157:800–804.

    Article  CAS  PubMed  Google Scholar 

  38. Hurle R, Losa A, Ranieri A, Graziotti P, Lembo A. Low dose pasteur bacillus Calmette-Guéin regimen in stage T1, grade 3 bladder cancer therapy. J Urol 1996;156:1602–1605.

    Article  CAS  PubMed  Google Scholar 

  39. Zhang GK, Uke ET, Sharer WC, Borkon WD, Bernstein SM. Reassessment of conservative management for stage T1N0M0 transitional cell carcinoma of the bladder. J Urol 1996;155:1907–1909.

    Article  CAS  PubMed  Google Scholar 

  40. Herr HW, Schwalb DM, Zhang Z-F, et al. Intravesical bacillus Calmette-Guéin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol 1995;13:1404–1408.

    CAS  PubMed  Google Scholar 

  41. Herr HW, Laudone VP, Badalament RA, et al. Bacillus Calmette-Guéin therapy alters the progression of superficial bladder cancer. J Clin Oncol 1998;6:1450–1455.

    Google Scholar 

  42. Herr HW, Wartinger DD, Fair WR, Oettgen HF. Bacillus Calmette-Guéin therapy for superficial bladder cancer: a 10-year followup. J Urol 1992;147:1020–1023.

    CAS  Google Scholar 

  43. Holmang S, Hedelin H, Anderstrom C, Holmberg E, Johansson SL. Long-term followup of a bladder carcinoma cohort: routine followup urography is not necessary. J Urol 1998;160:45–48.

    Article  CAS  PubMed  Google Scholar 

  44. Herr HW. Extravesical tumor relapse in patients with superficial bladder tumors. J Clin Oncol 1998;16:1099–1102.

    CAS  PubMed  Google Scholar 

  45. Yamashita T, Muraishi O, Umeda S, Matsushita T. Radical cystectomy using endoscopic stapling devices: preliminary experience with a simple and reliable technique. J Urol 1997;157:263–265.

    Article  CAS  PubMed  Google Scholar 

  46. Schoenberg MP, Walsh PC, Breazeale DR, Marshall FF, Mostin JL, Brendler CB. Local recurrence and survival following nerve sparing radical cystoprostatectomy for bladder cancer: 10-year followup. J Urol 1996;155:490–494.

    Article  CAS  PubMed  Google Scholar 

  47. Mills RD, Studer UE. Potential metabolic complications of continent urinary diversion. Contemp Urol 2001;May:110–114.

    Google Scholar 

  48. Hautmann RE, de Petriconi R, Gottfried H-W, Kleinschmidt K, Mattes R

    Google Scholar 

  49. Paiss T. The ileal neobladder: complications and functional results in 363 patients after 11 years of followup. J Urol 1999;161:422–428.

    Article  PubMed  Google Scholar 

  50. Schoenberg M, Hortopan S, Schlossberg L, Marshall FF. Anatomical anterior exenteration with urethral and vaginal preservation: illustrated surgical method. J Urol 1998;161:569–572.

    Article  Google Scholar 

  51. Shimogaki H, Okada H, Fujisawa M, et al. Long-term experience with orthotopic reconstruction of the lower urinary tract in women. J Urol 1999;161:573–577.

    Article  CAS  PubMed  Google Scholar 

  52. Hautmann RE, Paiss T, de Petriconi R. The ileal neobladder in women: 9 years of experience with 18 patients. J Urol 1996;155:76–81.

    Article  CAS  PubMed  Google Scholar 

  53. Pagano F, Bassi P, Galetti TP, et al. Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J Urol 1991;145:45–50.

    CAS  PubMed  Google Scholar 

  54. Vieweg J, Gschwend JE, Herr HW, Fair WR. Pelvic lymph node dissection can be curative in patients with node positive bladder cancer. J Urol 1999;161:449–454.

    Article  CAS  PubMed  Google Scholar 

  55. Vieweg J, Gschwend JE, Herr HW, Fair WR. The impact of primary stage on survival in patients with lymph node positive bladder cancer. J Urol 1999;161:72–76.

    Article  CAS  PubMed  Google Scholar 

  56. Logothetis CJ, Johnson DE, Chong C, et al. Adjuvant chemotherapy of bladder cancer: a preliminary report. J Urol 1988;139:1207–1211.

    CAS  PubMed  Google Scholar 

  57. Skinner DG, Dahiels JR, Russell CA, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991;145:459–464; discussion 464–467.

    CAS  PubMed  Google Scholar 

  58. Stockle M, Meyenburg W, Wellek S, et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 1992;148:302–307.

    CAS  Google Scholar 

  59. Herr HW, Bajorin DF, Scher HI. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. J Clin Oncol 1998;16(4):1298–1301.

    CAS  PubMed  Google Scholar 

  60. Solsona E, Iborra I, Ricos JV, Monros JL, Casanova J, Calabuig C. Feasibility of transurethral resection for muscle infiltrating carcinoma of the bladder: long-term followup of a prospective study. J Urol 1998;159:95–99.

    Article  CAS  PubMed  Google Scholar 

  61. McKiernan JM, Kaplan SA, Santarosa RP, Te AE, Sawczuk IS. Transurethral electrovaporization of bladder cancer. Urology 1996;48:207–210.

    Article  CAS  PubMed  Google Scholar 

  62. Sarkis AS, Bajorin DF, Reuter VE, et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 1995;13(6):1384–1390.

    CAS  PubMed  Google Scholar 

  63. Herr HW, Bajorin DF, Scher HI, Cordon-Cardo C, Reuter VE. Can p53 help select patients with invasive bladder cancer for bladder preservation? J Urol 1999;161:20–23.

    Article  CAS  PubMed  Google Scholar 

  64. McCaffrey JA, Bajorin DF, Scher HI, Bosl GJ. Combined-modality therapy for bladder cancer. Oncology 1997;11(suppl 9):18–26.

    CAS  PubMed  Google Scholar 

  65. Tester W, Caplan R, Heaney J, et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of radiation therapy oncology group phase II trial 8802. J Clin Oncol 1996;14:119–126.

    CAS  Google Scholar 

  66. Chauvet B, Brewer Y, Felix-Faure C, Davin J-L, Choquenet C, Reboul F. Concurrent cisplatin and radiotherapy for patients with muscle invasive bladder cancer who are not candidates for radical cystectomy. J Urol 1996;156:1258–1262.

    Article  CAS  PubMed  Google Scholar 

  67. Shipley WU, Winter KA, Kaufman DS, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of radiation therapy oncology group 89-3. J Clin Oncol 1998;16:3576–3583.

    CAS  PubMed  Google Scholar 

  68. Kaufman DS, Shipley WU, Griffin PP, et al. Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med 1993;329:1377–1382.

    Article  CAS  PubMed  Google Scholar 

  69. Kachnic LA, Kaufman DS, Heney NM, et al. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol 1997;15:1022–1029.

    CAS  PubMed  Google Scholar 

  70. Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methrotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997;15:2564–2569.

    CAS  PubMed  Google Scholar 

  71. Bajorin DF, McCaffrey JA, Hilton S, et al. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial. J Clin Oncol 1998;16:2722–2727.

    CAS  PubMed  Google Scholar 

  72. Sengelov L, Kamby C, Lund B, Engelholm SA. Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study. J Clin Oncol 1998;16:3392–3397.

    CAS  PubMed  Google Scholar 

  73. Vaughn DJ, Malkowicz SB, Zoltick B, et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J Clin Oncol 1998;16:255–260.

    CAS  PubMed  Google Scholar 

  74. Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996;2:521–530.

    CAS  PubMed  Google Scholar 

Download references

Authors
  1. James M. Kozlowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Norm Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Rush Medical College, Chicago, IL, 60612, USA

    Theodore J. Saclarides M.D. (Professor of Surgery, Head), Keith W. Millikan M.D. (Associate Professor of Surgery, Director of Undergraduate Surgical Education, Director) & Constantine V. Godellas M.D. (Associate Professor of Surgery, Academic Program Coordinator) (Professor of Surgery, Head),  (Associate Professor of Surgery, Director of Undergraduate Surgical Education, Director) &  (Associate Professor of Surgery, Academic Program Coordinator)

  2. Section of Colon and Rectal Surgery Department of General Surgery, Rush-Presbyterian-St. Luke’s Medical Center, Chicago, IL, 60612, USA

    Theodore J. Saclarides M.D. (Professor of Surgery, Head) (Professor of Surgery, Head)

  3. Nutrition Consultation Service Department of General Surgery, Rush-Presbyterian-St. Luke’s Medical Center, Chicago, IL, 60612, USA

    Keith W. Millikan M.D. (Associate Professor of Surgery, Director of Undergraduate Surgical Education, Director) (Associate Professor of Surgery, Director of Undergraduate Surgical Education, Director)

  4. Department of General Surgery, Rush-Presbyterian-St. Luke’s Medical Center, Chicago, IL, 60612, USA

    Constantine V. Godellas M.D. (Associate Professor of Surgery, Academic Program Coordinator) (Associate Professor of Surgery, Academic Program Coordinator)

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag New York, Inc.

About this chapter

Cite this chapter

Kozlowski, J.M., Smith, N. (2003). Cancer of the Bladder. In: Saclarides, T.J., Millikan, K.W., Godellas, C.V. (eds) Surgical Oncology. Springer, New York, NY. https://doi.org/10.1007/0-387-21701-0_47

Download citation

  • DOI: https://doi.org/10.1007/0-387-21701-0_47

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-95201-7

  • Online ISBN: 978-0-387-21701-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation